SCHEMBL6443884

SCHEMBL6443884

NC(=O)C(C=O)Cc1ccccc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 3/20 0.55
ALPI P09923 1/20 0.50
PKM P14618 1/20 0.50
PTGS1 P23219 1/20 0.50
XIAP P98170 1/20 0.50
SLC7A5 Q01650 1/20 0.50
CYP1A2 P05177 1/20 0.48
ALDH1A1 P00352 1/20 0.46
POLB P06746 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
SRR Q9GZT4 2/20 0.46
SLC1A3 P43003 2/20 0.46
SLC1A2 P43004 2/20 0.46
SLC1A1 P43005 2/20 0.46
MDM2 Q00987 1/20 0.44
SLC15A1 P46059 2/20 0.44
CES2 O00748 1/20 0.43
CES1 P23141 1/20 0.43
ANPEP P15144 1/20 0.43
LAP3 P28838 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6443176 1.00 EPHX1 (0.55) EPHX1ALPIPKMPTGS1XIAP
SCHEMBL2561452 0.84 CYP1A2 (0.57) EPHX1ALPIPKMPTGS1XIAP
SCHEMBL20016694 0.81 ALPI (0.50) EPHX1ALPIPKMPTGS1XIAP
SCHEMBL21464568 0.79 CYP1A2 (0.47) EPHX1ALPIPKMPTGS1XIAP
Benzene SCHEMBL28150184 0.79 ALPI (0.48) EPHX1ALPIPKMPTGS1XIAP
SCHEMBL9665756 0.77 MAPT (0.50) EPHX1ALPIPKMPTGS1XIAP
SCHEMBL8749105 0.77 KEAP1 (0.55) ALPIPKMPTGS1XIAPSLC7A5
SCHEMBL677369 0.77 MAPT (0.50) EPHX1ALPIPKMPTGS1XIAP
SCHEMBL7419761 0.77 CTSB (0.53) CYP1A2ALDH1A1L3MBTL1SLC15A1LAP3
SCHEMBL3184772 0.77 POLB (0.51) ALDH1A1POLBL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050130941-A1 Methods of treating alzheimer's disease PHARMACIA & UPJOHN COMPANY LLC 2005-06-16 US disclosed
EP-1392315-A1 METHODS OF TREATING ALZHEIMER'S DISEASE Elan Pharmaceuticals, Inc. (US) 2004-03-03 EP disclosed
WO-2002100410-A1 METHODS OF TREATING ALZHEIMER'S DISEASE ELAN PHARMACEUTICALS, INC. (US) 2002-12-19 WO disclosed
US-5753652-A Antiretroviral hydrazine derivatives NOVARTIS CORPORATION (US) 1998-05-19 US disclosed
EP-0604368-B1 Anti retroviral hydrazine derivatives CIBA GEIGY AG (CH) 1996-09-18 EP disclosed
EP-0604368-A1 Anti retroviral hydrazine derivatives CIBA-GEIGY AG (CH) 1994-06-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050130941-A1 Methods of treating alzheimer's disease BACE1, PSEN1, BACE2 EPHX1 532/4885ALPI 994/4885PKM 2587/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.